MA40219B1 - Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide - Google Patents

Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Info

Publication number
MA40219B1
MA40219B1 MA40219A MA40219A MA40219B1 MA 40219 B1 MA40219 B1 MA 40219B1 MA 40219 A MA40219 A MA 40219A MA 40219 A MA40219 A MA 40219A MA 40219 B1 MA40219 B1 MA 40219B1
Authority
MA
Morocco
Prior art keywords
acetylpiperidin
dihydroisoquinolin
carboxamide
hydroxypropyl
amino
Prior art date
Application number
MA40219A
Other languages
English (en)
Other versions
MA40219A (fr
Inventor
William M Clark
Rajendra S Sathe
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40219A publication Critical patent/MA40219A/fr
Publication of MA40219B1 publication Critical patent/MA40219B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux sels cristallins de(s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide et des compositions pharmaceutiques les contenant. L'invention concerne également leurs procédés de préparation et leurs procédés d'utilisation.
MA40219A 2014-06-25 2015-06-23 Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide MA40219B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016819P 2014-06-25 2014-06-25
PCT/IB2015/054712 WO2015198229A1 (fr) 2014-06-25 2015-06-23 Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Publications (2)

Publication Number Publication Date
MA40219A MA40219A (fr) 2017-05-03
MA40219B1 true MA40219B1 (fr) 2021-08-31

Family

ID=53510948

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40219A MA40219B1 (fr) 2014-06-25 2015-06-23 Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Country Status (29)

Country Link
US (2) US9884846B2 (fr)
EP (1) EP3160958B1 (fr)
JP (1) JP6559719B2 (fr)
KR (1) KR102493854B1 (fr)
CN (1) CN106536511B (fr)
AU (1) AU2015278728B2 (fr)
BR (1) BR112016030586B1 (fr)
CA (1) CA2952567A1 (fr)
CL (1) CL2016003278A1 (fr)
CR (1) CR20160598A (fr)
CY (1) CY1124085T1 (fr)
DK (1) DK3160958T3 (fr)
DO (1) DOP2016000333A (fr)
EA (1) EA032017B1 (fr)
ES (1) ES2869374T3 (fr)
HR (1) HRP20210681T1 (fr)
HU (1) HUE054454T2 (fr)
IL (1) IL249491A0 (fr)
LT (1) LT3160958T (fr)
MA (1) MA40219B1 (fr)
MX (1) MX2017000134A (fr)
PE (1) PE20170146A1 (fr)
PH (1) PH12016502523A1 (fr)
PL (1) PL3160958T3 (fr)
PT (1) PT3160958T (fr)
RS (1) RS61731B1 (fr)
SG (1) SG11201610709UA (fr)
SI (1) SI3160958T1 (fr)
WO (1) WO2015198229A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CA2953572A1 (fr) * 2014-08-04 2016-02-11 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP3706747A4 (fr) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
CR20200263A (es) 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CA3141748A1 (fr) 2019-06-10 2020-12-17 Lupin Limited Inhibiteurs de prmt5
BR112022007808A2 (pt) 2019-10-22 2022-07-05 Lupin Ltd Combinação farmacêutica de inibidores de prmt5
EP4069698A1 (fr) 2019-12-03 2022-10-12 Lupin Limited Analogues nucléosidiques substitués en tant qu'inhibiteurs de prmt5
CN112206218B (zh) * 2020-10-24 2022-08-23 迪沙药业集团有限公司 一种甲硝唑维生素b6组合物
WO2024038004A1 (fr) 2022-08-15 2024-02-22 Astrazeneca Ab Inhibiteurs de prmt5 à coopération avec la mta destinés à être utilisés dans le traitement du cancer
KR20240024419A (ko) * 2022-08-16 2024-02-26 제이투에이치바이오텍 (주) 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE150297T1 (de) 1992-06-10 1997-04-15 Nanosystems Llc Oberflaechenmodifizierte nsaid nanopartikeln
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
WO1998035666A1 (fr) 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
US9044432B2 (en) * 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
CN102199623A (zh) * 2011-03-22 2011-09-28 中国科学院遗传与发育生物学研究所 蛋白质精氨酸甲基转移酶5的新用途
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用

Also Published As

Publication number Publication date
CN106536511A (zh) 2017-03-22
LT3160958T (lt) 2021-04-12
AU2015278728B2 (en) 2018-01-18
BR112016030586B1 (pt) 2022-09-27
SI3160958T1 (sl) 2021-04-30
EP3160958B1 (fr) 2021-02-24
US20170190688A1 (en) 2017-07-06
US9981948B2 (en) 2018-05-29
IL249491A0 (en) 2017-02-28
KR102493854B1 (ko) 2023-01-30
MX2017000134A (es) 2017-05-01
BR112016030586A2 (fr) 2017-08-22
PT3160958T (pt) 2021-04-07
HRP20210681T1 (hr) 2021-06-11
HUE054454T2 (hu) 2021-09-28
MA40219A (fr) 2017-05-03
JP6559719B2 (ja) 2019-08-14
JP2017519027A (ja) 2017-07-13
ES2869374T3 (es) 2021-10-25
AU2015278728A1 (en) 2017-01-12
CL2016003278A1 (es) 2017-06-02
DK3160958T3 (da) 2021-04-12
RS61731B1 (sr) 2021-05-31
EA201692465A1 (ru) 2017-05-31
WO2015198229A1 (fr) 2015-12-30
SG11201610709UA (en) 2017-01-27
EP3160958A1 (fr) 2017-05-03
CY1124085T1 (el) 2022-05-27
KR20170019464A (ko) 2017-02-21
CN106536511B (zh) 2019-04-30
AU2015278728A8 (en) 2017-02-02
CR20160598A (es) 2017-03-10
PE20170146A1 (es) 2017-03-08
PL3160958T3 (pl) 2021-07-19
US9884846B2 (en) 2018-02-06
EA032017B1 (ru) 2019-03-29
CA2952567A1 (fr) 2015-12-30
PH12016502523A1 (en) 2017-04-10
US20180099948A1 (en) 2018-04-12
DOP2016000333A (es) 2017-02-28

Similar Documents

Publication Publication Date Title
MA40219A (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
MA49093B1 (fr) 4-amino-6-(hétérocycliques)picolinates et 6-amino-2-(hétérocyclique)pyrimidine-4-carboxylates et leur utilisation en tant qu'herbicides
PH12018500259A1 (en) Muscarinic agonists
PH12016501440A1 (en) Novel heterocyclic compounds
PH12016501570A1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
MA44637B1 (fr) Composes hétérocycliques et leurs utilisations
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
MY193728A (en) Muscarinic receptor agonists
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201100032A1 (ru) Соединения пиридина
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
EA201891315A1 (ru) Твердые дисперсии, содержащие стимулятор sgc
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
TR201909997T4 (tr) 5-HT4 reseptör agonistleri olarak amid bileşikleri.
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.